Brief: Janone Says Co Encouraged By Recent FDA Communications Regarding Phase 2B Clinical Trial Design Of Lead Drug Candidate JAN101
28/09/2021 21:10
Sept 28 (Reuters) - Janone Inc JAN.O :
* JANONE ENCOURAGED BY RECENT FDA COMMUNICATIONS REGARDING
PHASE
2B CLINICAL TRIAL DESIGN OF LEAD DRUG CANDIDATE JAN101
* JANONE - WORKING WITH PARTNERS TO INCORPORATE ALL
RECOMMENDATIONS, COMMENTS PROVIDED BY FDA INTO PHASE 2B
PROTOCOL, SUPPORTING DOCUMENTS
Source text for Eikon: ID:nPn7KVf3Wa
Further company coverage: JAN.O
Recent news on AI Financial
See all newsBrief: ALT5 Sigma Corporation Restores Compliance With Nasdaq Periodic Filing Requirements
Brief: Alt5 Sigma Expects To File Its Quarterly Report On Form 10-Q
Media: Trump-linked crypto venture Alt5 Sigma retains auditor - FT
Brief: ALT5 Sigma Corporation Provides Corporate Update
American Bitcoin steadies after share lock-up expiry sparks near 40% plunge (updated)